[Newsmp] In March this year, institutional investors who had largely liquidated their stake in Celltrion started courting again.
Individual investors regained their loyalty to Shinpoong Pharmaceutical and Celltrion and bought Ildong Pharmaceutical.
According to the Korean Exchange, institutional investors, who sold Celltrion a net of KRW 223.9 billion in January and more than KRW 30 billion in February, net bought more than KRW 200 billion in March.
They also tended to focus on the three major bio companies, purchasing a net KRW 25~29 billion from SK Bioscience and Samsung Biologics, even though it was relatively small compared to Celltrion.
Other than these, institutional investors net bought KRW 24.7 billion of GC Pharma and KRW 19.4 billion of Hanmi Pharmaceutical, and there are no pharmaceutical stocks exceeded KRW 10 billion in net sales.
During the same period, individual investors net purchased KRW 90.4 billion of Shinpoong Pharmaceutical, KRW 86.8 of Celltrion, and KRW 67.9 billion of Ildong Pharmaceutical. In addition, net purchases of SK Bioscience and Ildong Holdings also greatly exceeded KRW 20 billion.
On the other hand, they net sold KRW 62 billion of Samsung Biologics, KRW 27.6 billion of Daewoong Pharmaceutical, KRW 18.8 billion of GC Pharma, and KRW 18.7 billion of Hanmi Pharmaceutical.
Foreign investors liquidated Celltrion, Shinpoong Pharmaceutical, and SK Bioscience.
In particular, net selling by foreign investors to Celltrion reached KRW 364.8 billion, and Shinpoong Pharmaceutical KRW 90.6 billion.
Net sales to SK Bioscience also amounted to KRW 62.9 billion, and Ildong Pharmaceutical KRW 16.6 billion, exceeding KRW 10 billion.
In the meantime, foreign investors bought a net KRW 39.3 billion of Samsung Biologics and KRW 21.3 billion for Daewoong Pharmaceutical.
